Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) is projected to post its Q4 2024 quarterly earnings results before the market opens on Monday, March 10th. Analysts expect Fennec Pharmaceuticals to post earnings of $0.56 per share and revenue of $16.42 million for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.
Fennec Pharmaceuticals Price Performance
Shares of NASDAQ FENC traded up $0.29 during mid-day trading on Tuesday, reaching $6.40. 124,816 shares of the company traded hands, compared to its average volume of 111,660. Fennec Pharmaceuticals has a fifty-two week low of $3.96 and a fifty-two week high of $11.49. The firm has a market cap of $176.40 million, a PE ratio of -63.99 and a beta of 0.36. The stock has a fifty day simple moving average of $6.39 and a 200-day simple moving average of $5.61.
Insider Buying and Selling
In other Fennec Pharmaceuticals news, Director Rosty Raykov sold 10,000 shares of the company's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $6.08, for a total transaction of $60,800.00. Following the completion of the sale, the director now directly owns 83,863 shares of the company's stock, valued at approximately $509,887.04. This represents a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 31,186 shares of company stock worth $203,389 in the last three months. 10.98% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on FENC. Stephens upgraded Fennec Pharmaceuticals to a "strong-buy" rating in a research report on Monday, November 18th. Wedbush reaffirmed an "outperform" rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a report on Monday. Finally, HC Wainwright reiterated a "buy" rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research report on Tuesday.
Check Out Our Latest Stock Analysis on FENC
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Recommended Stories
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
